These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 12772496)

  • 1. Web alert. Oligonucleotide, antibody and peptide therapeutics.
    Stephens AC
    Curr Opin Mol Ther; 2003 Apr; 5(2):95-6. PubMed ID: 12772496
    [No Abstract]   [Full Text] [Related]  

  • 2. Oligonucleotide, antibody and peptide therapeutics--from design to the clinic.
    Goodchild J
    Curr Opin Mol Ther; 2004 Apr; 6(2):119. PubMed ID: 15195921
    [No Abstract]   [Full Text] [Related]  

  • 3. Development trends for monoclonal antibody cancer therapeutics.
    Reichert JM; Valge-Archer VE
    Nat Rev Drug Discov; 2007 May; 6(5):349-56. PubMed ID: 17431406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular target therapy for malignant lymphoma].
    Suzuki R
    Rinsho Ketsueki; 2008 Jan; 49(1):18-29. PubMed ID: 18277592
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development.
    Hermiston TW; Kirn DH
    Mol Ther; 2005 Apr; 11(4):496-507. PubMed ID: 15771953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of antisense nucleic acid molecules.
    Opalinska JB; Gewirtz AM
    Sci STKE; 2003 Oct; 2003(206):pe47. PubMed ID: 14583589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody therapeutics and apoptosis.
    Ludwig DL; Pereira DS; Zhu Z; Hicklin DJ; Bohlen P
    Oncogene; 2003 Dec; 22(56):9097-106. PubMed ID: 14663488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacologic characteristics and clinical activity of human rituximab anti-CD20 monoclonal antibody].
    Varaldo R; Gobbi M
    Ann Ital Med Int; 2003; 18(3):182-7. PubMed ID: 14621431
    [No Abstract]   [Full Text] [Related]  

  • 9. Intracellular delivery of oligonucleotide conjugates and dendrimer complexes.
    Juliano RL
    Ann N Y Acad Sci; 2006 Oct; 1082():18-26. PubMed ID: 17145920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-oligonucleotide conjugates form stable and selective complexes with antibody and DNA.
    Tennilä T; Antopolsky M; Azhayev A; Azhayeva E
    Bioconjug Chem; 2008 Jul; 19(7):1361-7. PubMed ID: 18529023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing human genetic diseases with oligonucleotide-based therapies.
    Martínez T; Wright N; López-Fraga M; Jiménez AI; Pañeda C
    Hum Genet; 2013 May; 132(5):481-93. PubMed ID: 23494242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A novel paradigm and new targets in cancer therapy].
    Novik AA; Kamilova TA; Tsygan VN
    Vopr Onkol; 2003; 49(6):695-704. PubMed ID: 14976912
    [No Abstract]   [Full Text] [Related]  

  • 13. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
    LaCasce AS; Freedman AS
    Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technology evaluation: GEM-231, Hybridon.
    Yeung PK
    Curr Opin Mol Ther; 2003 Jun; 5(3):315-20. PubMed ID: 12870443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Building oligonucleotide therapeutics using non-natural chemistries.
    Wilson C; Keefe AD
    Curr Opin Chem Biol; 2006 Dec; 10(6):607-14. PubMed ID: 17049298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era.
    Juliano RL; Astriab-Fisher A; Falke D
    Mol Interv; 2001 Apr; 1(1):40-53. PubMed ID: 14993337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
    Bengtson KL; Skinner MA; Ware RE
    J Pediatr; 2003 Nov; 143(5):670-3. PubMed ID: 14615744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.
    Napoli S; Negri U; Arcamone F; Capobianco ML; Carbone GM; Catapano CV
    Nucleic Acids Res; 2006; 34(2):734-44. PubMed ID: 16449206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.